A Nonrandomized Dose-escalation Study of Clofarabine in Combination With Gemtuzumab Ozogamicin for Relapsed/Refractory Acute Myeloid Leukemia (AML) for Patients Less Than 60 Years-old.

Trial Profile

A Nonrandomized Dose-escalation Study of Clofarabine in Combination With Gemtuzumab Ozogamicin for Relapsed/Refractory Acute Myeloid Leukemia (AML) for Patients Less Than 60 Years-old.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2015

At a glance

  • Drugs Clofarabine (Primary) ; Gemtuzumab ozogamicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Oct 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 28 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
    • 22 May 2012 Actual patient number 21 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top